Higher incidence of mild cognitive impairment in familial hypercholesterolemia
- PMID: 20193836
- PMCID: PMC2844655
- DOI: 10.1016/j.amjmed.2009.08.015
Higher incidence of mild cognitive impairment in familial hypercholesterolemia
Abstract
Objective: Hypercholesterolemia is an early risk factor for Alzheimer's disease. Low-density lipoprotein (LDL) receptors might be involved in this disorder. Our objective was to determine the risk of mild cognitive impairment in a population of patients with heterozygous familial hypercholesterolemia, a condition involving LDL receptor dysfunction and lifelong hypercholesterolemia.
Methods: By using a cohort study design, patients with familial hypercholesterolemia (N=47) meeting inclusion criteria and comparison patients without familial hypercholesterolemia (N=70) were consecutively selected from academic specialty and primary care clinics, respectively. All patients were older than 50 years. Those with disorders that could affect cognition, including history of stroke or transient ischemic attacks, were excluded from both groups. Thirteen standardized neuropsychologic tests were performed in all subjects. Mutational analysis was performed in patients with familial hypercholesterolemia, and brain imaging was obtained in those with familial hypercholesterolemia and mild cognitive impairment.
Results: Patients with familial hypercholesterolemia showed a high incidence of mild cognitive impairment compared with those without familial hypercholesterolemia (21.3% vs 2.9%; P=.00). This diagnosis was unrelated to structural pathology or white matter disease. There were significant differences, independent of apolipoprotein E4 or E2 status, between those with familial hypercholesterolemia and those with no familial hypercholesterolemia in several cognitive measures, all in the direction of worse performance for those with familial hypercholesterolemia.
Conclusion: Because prior studies have shown that older patients with sporadic hypercholesterolemia do not show a higher incidence of mild cognitive impairment, the findings presented suggest that early exposure to elevated cholesterol or LDL receptor dysfunction may be risk factors for mild cognitive impairment.
2010 Elsevier Inc. All rights reserved.
Conflict of interest statement
None of the authors report any conflicts of interest.
Similar articles
-
The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.Dan Med Bull. 2002 Nov;49(4):318-45. Dan Med Bull. 2002. PMID: 12553167 Review.
-
Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia.Am J Cardiol. 2008 Nov 1;102(9):1187-93, 1193.e1. doi: 10.1016/j.amjcard.2008.06.056. Epub 2008 Aug 27. Am J Cardiol. 2008. PMID: 18940289
-
Relationship of Familial Hypercholesterolemia and High Low-Density Lipoprotein Cholesterol to Ischemic Stroke: Copenhagen General Population Study.Circulation. 2018 Aug 7;138(6):578-589. doi: 10.1161/CIRCULATIONAHA.118.033470. Circulation. 2018. PMID: 29593013
-
Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship.Circ Cardiovasc Genet. 2016 Dec;9(6):504-510. doi: 10.1161/CIRCGENETICS.116.001545. Epub 2016 Oct 26. Circ Cardiovasc Genet. 2016. PMID: 27784735
-
Statins for children with familial hypercholesterolemia.Cochrane Database Syst Rev. 2019 Nov 7;2019(11):CD006401. doi: 10.1002/14651858.CD006401.pub5. Cochrane Database Syst Rev. 2019. PMID: 31696945 Free PMC article.
Cited by
-
Links between copper and cholesterol in Alzheimer's disease.Front Physiol. 2013 May 16;4:111. doi: 10.3389/fphys.2013.00111. eCollection 2013. Front Physiol. 2013. PMID: 23720634 Free PMC article.
-
Cholesterol: its regulation and role in central nervous system disorders.Cholesterol. 2012;2012:292598. doi: 10.1155/2012/292598. Epub 2012 Oct 17. Cholesterol. 2012. PMID: 23119149 Free PMC article.
-
Apolipoprotein E ε-4 as a genetic determinant of Alzheimer's disease heterogeneity.Degener Neurol Neuromuscul Dis. 2015 Jun 12;5:9-18. doi: 10.2147/DNND.S41721. eCollection 2015. Degener Neurol Neuromuscul Dis. 2015. PMID: 32669910 Free PMC article. Review.
-
Lipids and Alzheimer's Disease.Int J Mol Sci. 2020 Feb 22;21(4):1505. doi: 10.3390/ijms21041505. Int J Mol Sci. 2020. PMID: 32098382 Free PMC article. Review.
-
Cerebrovascular Changes and Neurodegeneration Related to Hyperlipidemia: Characteristics of the Human ApoB-100 Transgenic Mice.Curr Pharm Des. 2020;26(13):1486-1494. doi: 10.2174/1381612826666200218101818. Curr Pharm Des. 2020. PMID: 32067608 Free PMC article.
References
-
- Masters CL, Beyreuther K. Alzheimer’s centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway. Brain. 2006;129:2823–2839. - PubMed
-
- Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–308. - PubMed
-
- Glenner GG, Wong CW. Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120:885–890. - PubMed
-
- Pappolla MA, Smith MA, Bryant-Thomas T, et al. Cholesterol, oxidative stress, and Alzheimer’s disease: expanding the horizons of pathogenesis. Free Radic Biol Med. 2002;33:173–181. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical